Formulation: A solid
Formal Name: 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl-d4]methyl]-2,4-thiazolidinedione
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C24H23D4NO5S
Formula Weight: 445,6
Shelf life (days): 1460
CAS Number: 2749370-85-0
Notes: Troglitazone-d4 is intended for use as an internal standard for the quantification of troglitazone (Item No. 71750) by GC- or LC-MS. Troglitazone is a selective agonist of peroxisome proliferator-activated receptor γ (PPARγ; EC50s = 0.78 and 0.55 μM for the mouse and human receptors, respectively, in a transactivation assay).{10670} It is selective for PPARγ over PPARα and PPARδ, at which it is inactive at concentrations up to 10 μM. Troglitazone (500 mg/kg twice per day) exhibits antihyperglycemic and antihyperlipidemic properties in Zucker diabetic fatty rats, reducing plasma glucose and triglyceride levels by 61 and 87%, respectively.{25251} It also induces cell cycle arrest at the G1 phase in SK-HEP-1 and Hep3B hepatocellular carcinoma cells when used at a concentration of 10 μM and increases apoptosis in these cells at concentrations of 30 μM and higher.{10669}